New oral drug for inflammatory bowel disease enters first human tests
NCT ID NCT07632573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests BDHK-2009, an experimental tablet for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. The study involves 68 healthy adults aged 18 to 55 to see if the drug is safe and how the body handles it. Participants receive either a single dose or multiple doses of the drug or a placebo, with close monitoring for side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BDHK-2009
What this could lead to
If safe and effective in later trials, BDHK-2009 could become a new oral treatment option for people with ulcerative colitis or Crohn's disease.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only tests safety and how the drug moves through the body, not whether it works for the disease. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBD (INFLAMMATORY BOWEL DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Xiaoshan Hospital
RECRUITINGHangzhou, Zhejiang, 311200, China
Contact Phone: •••-•••-•••• Email: •••••@•••••